Bainan Biotech is a spinout company which is founded on years of research exploring the connection between gut hormones and bone turnover, carried out at the University of Copenhagen. We aim to utilise the natural responses to eating in order to promote the formation of stronger and healthier bone tissue and develop effective treatments for osteoporosis. Specifically, we are adapting our products to be effective in premenopausal women, a patient group which currently is vastly under-served in this area.
Our Target Patients
Osteoporosis is a condition of deteriorating bone mineralisation, resulting in increased risk of fractures. It is silently progressing over time posing a need to stop the disease process and prevent the weakening of the bones. Secondary osteoporosis, in particular among pre-menopausal women, is insufficiently treated as the widely used drugs for post-menopausal osteoporosis cannot be used due to teratogenicity, carcinogenicity, strong rebound effects, or lack of efficacy in this group.
1 in 100 women will suffer from Anorexia Nervosa at some point in their lifetime.
38% of anorectic patients develop osteoporosis and 92% develop osteopenia.
1 in 200 women are prescribed glucocorticoids.
Glucocorticoid use is the most common cause of secondary osteoporosis. High dose use can induce bone loss as rapid as 5-15% per annum
GLP-2/GIP and Bone Metabolism
Bone remodeling is a process of bone formation and bone resorption. Bone turnover has a marked circadian variation, with higher bone resorption during night time and a correspondingly lower resorption during the day time.The mechanism regulating this rhythm seems to be related to food intake. We and others have shown that gut hormones are involved, as we have shown that GLP-2 inhibits bone resorption, and that treating humans with GLP-2 results in increased bone mineral density. Furthermore, we have recently showed that GIP also affects bone metabolism in man.
The Bainan Approach
Created upon a thorough analysis of receptor ligand interactions for the GIP and the GLP-2 system, structural information of receptors and peptide hormones, we have successfully created a series of dual-agonists with nano-molar potency. We also modified these with lipidations to prolong their half-life and cross-checked for selectivity against class B1 (secretin-like) GPCRs. A rat model was developed for efficacy and toxicity testing in vivo, and several human studies were initiated, focusing on subcutaneous injections of GIP and GLP-2 at two doses, separately and combined. Our groundbreaking human studies demonstrate that combined administration of GIP and GLP-2 have synergistic effects on bone remodeling, both in healthy young men and osteopenic women, and showed for the first time, that GIP in addition to reducing bone resorption (like GLP-2) also increase bone formation.